marijuana stock news

Blue Line Protection Group, Inc. (BLPG)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014
Total Revenue 520   475   269   237  
Cost of Revenue 368 291 262 221
Gross Profit 152   185   7   16  
Operating Expenses
Research Development – – – –
Selling General and Administrative 491 364 747 1,635
Non Recurring – – – –
Others 10 10 9 8
Total Operating Expenses – – – –
Operating Income or Loss (349) (189) (749) (1,626)
Income from Continuing Operations
Total Other Income/Expenses Net 2 207 2 1
Earnings Before Interest And Taxes (347) 18 (747) (1,625)
Interest Expense 25 11 – –
Income Before Tax (371) 7 (747) (1,625)
Income Tax Expense – – – –
Minority Interest – – – –
Net Income From Continuing Ops (371) 7 (747) (1,625)
Non-recurring Events
Discontinued Operations – – – –
Extraordinary Items – – – –
Effect Of Accounting Changes – – – –
Other Items – – – –
Net Income (371) 7   (747) (1,625)
Preferred Stock And Other Adjustments – – – –
Net Income Applicable To Common Shares (371) 7   (747) (1,625)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AbbVie (ABBV) and EvolveImmune Therapeutics Announce Collaboration

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation…

HEXO Corp. (HEXO) and Entourage Health Sign Long-Term Supply Agreement

HEXO and Entourage Health Sign Long-Term Supply Agreement HEXO Corp. (TSX: HEXO;…

$VGPR Sets Date for Shareholder Conference Call

Vega Biofuels Sets Date for Shareholder Conference Call Company to Discuss Current…

Cara Therapeutics, Inc. (CARA) Doses First Patient in Phase 1 Trial of Oral KORSUVA™

Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™…